What do systematic reviews say?

Intervention not reported

The intervention leads to lower overall survival1 (high certainty).

• Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
  HR 0.87 [0.79, 0.96]
  4 studies · 2018 participants
  High

Intervention not reported

The intervention showed no clear difference in progression‐free survival1 (low certainty).

• Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
  HR 0.91 [0.83, 1]
  4 studies · 2018 participants
  Low

Intervention not reported

The intervention leads to higher one‐year survival rate2 (high certainty).

• Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
  RR 1.13 [1.02, 1.25]
  4 studies · 2018 participants
  High

Intervention not reported

The intervention may leads to higher objective response rate2 (low certainty).

• Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
  RR 1.31 [1.14, 1.51]
  4 studies · 2018 participants
  Low

Intervention not reported

• Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1801 participants
  Low

Intervention not reported

The intervention may leads to higher serious adverse events2,4 (low certainty).

• Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
  RR 37.36 [10.66, 130.95]
  1 study · 4 participants
  Low

Intervention not reported

The intervention probably leads to lower lymph node mets analysis ‐ N+ OS (moderate certainty).

• Post‐surgical chemotherapy versus surgery alone for resectable gastric cancer 2013 · Cochrane Headline outcomes only
  HR 0.78 [0.67, 0.91]
  4 studies · 877 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in stage OS analysis ‐ T1/2 OS (moderate certainty).

• Post‐surgical chemotherapy versus surgery alone for resectable gastric cancer 2013 · Cochrane Headline outcomes only
  HR 0.86 [0.71, 1.05]
  5 studies · 1146 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in stage OS analysis ‐ T3/4 OS (moderate certainty).

• Post‐surgical chemotherapy versus surgery alone for resectable gastric cancer 2013 · Cochrane Headline outcomes only
  HR 0.66 [0.41, 1.08]
  4 studies · 1008 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in lymph node mets analysis ‐ N‐ OS (moderate certainty).

• Post‐surgical chemotherapy versus surgery alone for resectable gastric cancer 2013 · Cochrane Headline outcomes only
  HR 0.74 [0.41, 1.33]
  2 studies · 402 participants
  Moderate